dna-encoded-library
(2)
Rapafusyn Pharmaceuticals
Rapafusyn Pharmaceuticals is a Baltimore-based, clinical-stage drug discovery company spun out of Johns Hopkins University. Its RapaGlue platform designs non-degrading, cell-permeable macrocyclic molecular glues that modulate hard-to-drug intracellular and transmembrane targets - drawing on a proprietary DNA-encoded library of more than 8 billion compounds and machine learning for target selection. The lead program, RAP-0001, is a selective ENT1 inhibitor advancing toward IND-enabling studies for the prevention of acute kidney injury in cardiac surgery patients, with a broader pipeline spanning oncology, immunology, and pain.
Totus Medicines
Totus Medicines is a clinical-stage precision medicines company in Emeryville, California, building covalent small-molecule drugs against historically undruggable targets. Its AI-powered OmniDEL platform screens billions of DNA-encoded covalent candidates against thousands of targets inside living cells, surfacing molecules that older methods miss. Its lead program, TOS-358, is the first and only covalent PI3Ka inhibitor in clinical development, showing class-leading tolerability and strong disease control in breast, endometrial, and head & neck cancers.